Epithalon is the flagship product of a four-decade Soviet and Russian research program into short tissue-specific peptides claimed to reset aging biology, including telomerase activation and measurable mortality reduction in a 266-patient cohort. The mechanism is genuinely interesting. The evidence supporting it has a single-institution problem Western science hasn't been able to get past for over twenty years.
Peptides
-
Epithalon and the Khavinson Bioregulators -
GHK-Cu: The Copper Peptide and the Injectable Leap GHK-Cu is a rare grey-market peptide with genuinely strong topical evidence behind it — decades of published dermatology research and real randomized trials on skin and wound healing. The injectable, systemic anti-aging version sold today is a different claim entirely, resting on animal data and gene-expression studies that were never designed to prove what the injection ads imply.
-
TB-500 and the Thymosin Beta-4 Evidence Gap TB-500 is sold across grey-market vendors as a fast-track tissue-repair peptide, built on real cell biology involving actin sequestration and angiogenesis. It also entered human wellness circles by way of a veterinary doping scandal, not a clinical development program, and as of 2026 has never completed a published human trial for any indication.
-
AOD-9604 and the GH Fragment Marketing Gap AOD-9604 is a growth-hormone-derived fragment peptide sold widely today as a fat-loss and joint-repair compound, built on a genuinely clever piece of 1990s endocrinology — a lipolytic domain isolated from the rest of the GH molecule. It also failed its own Phase 2b obesity trial in 2007. Both facts matter, and only one of them shows up in the marketing.
-
BPC-157 and the Research-Peptide Gray Market BPC-157 has a real, unusually stable structure and a genuinely striking animal-trial record — and almost no controlled human data, an FDA compounding ban, and a supply chain that self-injects with no regulatory floor under it. Here's what the evidence actually supports.
-
CagriSema and the Amylin Comeback Pairing a long-acting amylin analog with semaglutide was supposed to be Novo Nordisk's answer to tirzepatide. The REDEFINE program shows a real, large effect — and a head-to-head trial showing it still isn't quite enough.
-
Collagen Peptides: What the Evidence Actually Says Collagen supplements get digested like any other protein, which should mean they can't reach your skin intact — except a specific dipeptide reliably does. The mechanism is real and measurable. Whether it translates into a benefit worth paying for depends heavily on who funded the trial you're reading.
-
GHRH and GHRP Secretagogues: Asking the Pituitary Instead of Replacing It Sermorelin, ipamorelin, and their relatives don't put growth hormone into your body — they ask your pituitary to make more of its own, through two distinct receptor pathways that leave the body's natural feedback loop intact. That distinction is real, but it doesn't make the anti-aging marketing built on top of it true.
-
GLP-2 Analogs for Short Bowel While GLP-1 dominates headlines for appetite suppression, its sibling hormone GLP-2 does the opposite job entirely: growing intestinal tissue back. Apraglutide and glepaglutide are the next generation of a small, rare-disease drug class built on that trophic signal.
-
MariTide and the Antagonist Paradox Amgen's maridebart cafraglutide blocks the same receptor tirzepatide activates, still produces close to 20% weight loss, and does it from a monthly injection instead of a weekly one — an antibody-format peptide drug with a genuinely unresolved mechanism and a real tolerability problem.
-
Melanotan and the Peptide Underground The same 1980s skin-cancer-prevention research that produced an FDA-approved drug for a rare light-sensitivity disorder also produced melanotan II — a gray-market tanning peptide whose non-selective receptor binding causes the appetite and libido effects users chase and the mole changes, priapism, and cardiac events regulators warn about.
-
Multi-Receptor Peptide Design: One Molecule, Several Targets Tirzepatide hits two receptors and retatrutide hits three, and neither is a gimmick. Here's how agonism, antagonism, and biased signaling actually work at the receptor level, and why combining several of them in one peptide became the dominant strategy in metabolic drug design.
-
Oral Peptide Delivery: Getting a Molecule Past the Gut Alive Peptides are built to be destroyed by digestion, which is exactly what makes swallowing them as a drug so hard. Here's why the gut is a molecular gauntlet, and how SNAC, enteric coatings, robotic capsules, and nanoparticles are each trying to beat it.
-
Petrelintide and the Amylin-Only Bet Zealand Pharma's petrelintide drops the GLP-1 component entirely and still produced 10.7% weight loss with placebo-like tolerability in its lead Phase 2 trial — a real test of whether amylin alone can compete with the incretin class, backed by a $5.3 billion Roche partnership.
-
PT-141 (Bremelanotide) and the Arousal Pathway Bremelanotide is a real, FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder — and also one of the most heavily grey-marketed peptides in circulation, sold as "PT-141" nasal sprays and vials with no prescription and no oversight. Both facts are true at once, and the gap between them is worth understanding on its own mechanistic terms.
-
Retatrutide: The Triple Agonist Pushing Past Tirzepatide Retatrutide's third receptor mechanism has produced the largest weight-loss and liver-fat numbers of any peptide therapeutic tested so far, and an eight-trial Phase 3 program to match. It also has a documented heart-rate signal the earlier drugs in its class don't carry.
-
Survodutide and Mazdutide: The Glucagon Bet Two GLP-1/glucagon dual agonists, developed an ocean apart by Boehringer Ingelheim and Innovent Biologics, are testing whether adding back a hormone that normally raises blood sugar can still produce a net metabolic win.
-
What a Peptide Actually Is: The Chemistry Between an Amino Acid and a Protein Peptide, polypeptide, protein — the words get used loosely, but the underlying chemistry is precise: one repeated bond, one repeated cellular assembly line, and a size boundary that isn't just semantic. How the ribosome actually builds a peptide chain, how the body tears one back down, and why that size boundary decides whether a drug can be a pill or has to be an injection.
-
The Huberman Lab Peptides Episode, Reviewed: What Dr. Bakri Said and What Survives Scrutiny In June 2026, Andrew Huberman spent nearly three hours with physician Abud Bakri walking through BPC-157, GHK-Cu, epithalon, pinealon, thymosin alpha-1, GLP-1s, and retatrutide. The episode is a genuinely useful map of what people are injecting and why. It is also a case study in how conversational time can flatten a very steep evidence gradient. A peptide-by-peptide fact-check of the claims, the mechanisms, and the regulatory maze in between.